Cognition Therapeutics, Inc.
CGTX
$1.01
-$0.03-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.64M | 2.70M | 2.52M | 2.60M | 2.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.74M | 8.82M | 13.67M | 6.38M | 13.98M |
| Operating Income | -7.74M | -8.82M | -13.67M | -6.38M | -13.98M |
| Income Before Tax | -3.93M | -4.57M | -3.34M | -4.93M | -6.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.93M | -4.57M | -3.34M | -4.93M | -6.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.93M | -4.57M | -3.34M | -4.93M | -6.73M |
| EBIT | -7.74M | -8.82M | -13.67M | -6.38M | -13.98M |
| EBITDA | -7.73M | -8.81M | -13.66M | -6.36M | -13.96M |
| EPS Basic | -0.04 | -0.05 | -0.04 | -0.06 | -0.11 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.02 | -0.04 | -0.07 |
| EPS Diluted | -0.04 | -0.05 | -0.04 | -0.06 | -0.11 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.02 | -0.04 | -0.07 |
| Average Basic Shares Outstanding | 90.62M | 89.19M | 88.60M | 77.95M | 63.69M |
| Average Diluted Shares Outstanding | 90.62M | 89.19M | 88.60M | 77.95M | 63.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |